$ISRG

GUTHART GARY S sold $4.0M of ISRG (indirect holdings)

GUTHART GARY S sold 10,000 indirectly-held shares of INTUITIVE SURGICAL INC (ISRG) at $400.00 ($4.00M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUTHART GARY S
Published Aug 12, 2026, 5:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 10,000 shares at $400/share on 2026-08-11, filed on 2026-08-12, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly react to insider selling headlines, but 10b5-1 context usually limits fundamental implications.

03

What to watch

The filing does not indicate reasons for sale, and the indirect ownership structure plus 10b5-1 timing can make the signal less informative than discretionary sales.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows director GUTHART GARY S sold 10,000 ISRG shares on 2026-08-11 for about $4.0M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The transaction is an open-market sale by a director, explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Even with a 10b5-1 plan, large dollar sales can still be interpreted by some traders as a mild bearish signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • INTUITIVE SURGICAL INC

    Company whose shares were sold in the reported Form 4 transaction.

  • GUTHART GARY S

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.